Hemolytic Anemia: Expert Subtype Diagnosis & Management

Hemolytic anemia is a condition in which red blood cells are destroyed faster than the bone marrow can replace them, causing anemia. Causes include autoimmune attack on red cells (AIHA), inherited genetic defects in red cell membranes or enzymes (hereditary spherocytosis, G6PD deficiency, pyruvate kinase deficiency), mechanical destruction in small blood vessels (TTP, HUS), complement dysregulation (PNH, aHUS), certain drugs, and infections including malaria and Mycoplasma pneumoniae. Each cause requires a distinct treatment approach.

The Direct Antiglobulin Test (DAT, or direct Coombs test) detects antibodies or complement proteins bound to the surface of red blood cells. A positive DAT indicates autoimmune hemolytic anemia (AIHA). The pattern identifies the subtype: IgG-positive with or without C3d indicates warm AIHA (responds to corticosteroids); C3d-positive only indicates cold agglutinin disease (steroids ineffective; complement inhibition needed). A negative DAT with ongoing hemolysis directs investigation toward hereditary, enzymatic, or mechanical causes of hemolysis.

Yes — thrombotic thrombocytopenic purpura (TTP) is a life-threatening hematologic emergency requiring immediate hospitalization and plasma exchange. TTP is caused by severely reduced ADAMTS13 enzyme activity, allowing microvascular platelet clots to mechanically destroy red blood cells and damage the brain and kidneys. Without prompt plasma exchange, mortality is high. When TTP is suspected on the basis of hemolytic anemia with schistocytes on blood smear, low platelets, and any neurologic or renal symptoms, emergency hematology evaluation and treatment must not be delayed.

There is currently no drug that corrects the G6PD enzyme deficiency. Management focuses on preventing acute hemolytic crises by strictly avoiding triggers — specific medications (primaquine, dapsone, nitrofurantoin, rasburicase), fava beans, and infections. Between episodes, most G6PD-deficient individuals have normal or near-normal hemoglobin with no chronic hemolysis. Gene therapy approaches for severe G6PD deficiency are in early research stages.

Mitapivat (Pyrukynd) is an oral allosteric activator of the pyruvate kinase-R (PK-R) enzyme, approved for adult patients with pyruvate kinase (PK) deficiency who are not regularly transfusion-dependent. By activating the deficient PK enzyme, mitapivat increases ATP production in red blood cells, improves their survival, reduces hemolysis, and raises hemoglobin. It is the first disease-modifying oral therapy for PK deficiency. Extension studies in transfusion-dependent adults and pediatric patients are ongoing.

Splenectomy is most clearly beneficial in hereditary spherocytosis and hereditary elliptocytosis or pyropoikilocytosis, where removing the spleen eliminates the site of premature RBC destruction and resolves hemolytic anemia in most patients. It is also considered in refractory warm AIHA that has failed steroids and rituximab. Splenectomy is not appropriate for cold agglutinin disease, TTP, or G6PD deficiency. Pre-splenectomy vaccination against encapsulated bacteria (pneumococcus, meningococcus, Hib) is mandatory, with lifelong penicillin prophylaxis required afterward.

Sutimlimab (Enjaymo) is an FDA-approved monoclonal antibody inhibiting C1s — a serine protease in the classical complement pathway. In cold agglutinin disease, IgM antibodies bind to red cells in cold temperatures and activate the classical complement cascade, triggering complement-mediated red cell destruction. By blocking C1s, sutimlimab prevents this cascade from proceeding, protecting red cells from complement attack. Administered by intravenous infusion, it rapidly reduces hemolysis, improves hemoglobin, and achieves transfusion independence in most CAD patients.

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder in which a PIGA gene mutation causes red blood cells to lack complement regulatory proteins CD55 and CD59, allowing complement to attack and destroy them (intravascular hemolysis). This causes dark morning urine, fatigue, and high risk of dangerous blood clots in unusual locations (cerebral veins, abdominal veins). Eculizumab or ravulizumab — terminal complement pathway inhibitors — dramatically reduce hemolysis, transfusion need, and thrombosis risk and are the standard of care for PNH.

Yes. CancerFax connects patients with hemolytic anemia to specialist hematologists for accurate subtype diagnosis, second opinion review, and access to advanced treatment options including sutimlimab for cold agglutinin disease, eculizumab and ravulizumab for PNH and aHUS, rituximab for refractory AIHA, mitapivat for pyruvate kinase deficiency, plasma exchange with caplacizumab for TTP, and clinical trials for novel complement and FcRn inhibitors. CancerFax can coordinate evaluation at leading hematology centers in India and internationally with expertise in rare blood disorders.